← Listen againIn Conversation
What Can One Brain Reveal About Alzheimer’s? October 16, 2026 · 8:27 · With Maya, Nora, and Alex
With me are Nora, our science and environment columnist, and Alex, our journalist. Thanks for joining us. Today’s question is: what can one brain reveal about Alzheimer’s disease?
Transcript Maya Welcome to Slow English FM. This is our round table, where we look at one subject from more than one angle and ask what the evidence can—and cannot—tell us. I’m Maya. With me are Nora, our science and environment columnist, and Alex, our journalist. Thanks for joining us. Today’s question is: what can one brain reveal about Alzheimer’s disease? Maya A study of one man’s brain has given researchers an unusual chance to compare nearby areas with very different levels of amyloid, a substance linked to Alzheimer’s. The areas with less amyloid also showed less of another form of damage, called tau tangles. But one case cannot show that clearing amyloid caused the difference. Nora, first, can you explain what the researchers saw, and why this comparison matters? Nora The account of the research in ScienceDaily, based on material from Penn Medicine, describes a man who was in his fifties when he was diagnosed with mild cognitive impairment caused by Alzheimer’s disease. He later took part in a clinical trial of aducanumab, an Alzheimer’s drug that targets amyloid. He received 30 doses over four and a half years. He died about four years after his last dose. After his death, researchers examined his brain. They found a striking difference between neighboring areas. Nora The surface of the brain has raised folds and grooves. In this man’s brain, the raised folds had lost most of their amyloid plaques and contained very little tau. The nearby grooves still had considerable amyloid. They also had much more tau, more inflammation, and more damage to brain tissue. Maya Let me check I have the main contrast. Areas with less amyloid also had less tau and less tissue damage. Is that what makes this case interesting? Nora Yes. Amyloid plaques are deposits that collect outside nerve cells. Tau is a protein inside nerve cells. In Alzheimer’s, abnormal tau can build up into tangles. Both are associated with damage to brain cells. In a typical study, it can be hard to compare what happens in different people, because people differ. Here, the researchers could compare nearby regions within the same brain. One area had much less amyloid; the next area had more. That offers a rare, close comparison. Alex And the timing is notable. The man died about four years after his last dose of aducanumab. So the examination showed a difference years after treatment had stopped. ScienceDaily’s account says the findings raise the possibility that substantial amyloid removal could be linked to changes in other disease processes over a longer period. That is a possibility suggested by this brain, not proof that the drug produced lasting protection. Maya Alex, what does that mean for the wider debate about amyloid drugs? Alex It gives a useful piece of evidence, but not a final answer. The pattern fits the idea that amyloid may be connected to later tau buildup and tissue damage. In the areas with little amyloid, there was little tau; in the areas that still had amyloid, there was more tau and more damage. That is a relationship researchers can study. But seeing two things together does not, by itself, prove that one caused the other. Nora Exactly. We should be careful with the word “cause.” The man’s brain was examined after his death, so researchers could map the pattern in detail. But this was one person, and the study cannot prove that removing amyloid was directly responsible for the difference in tau or tissue damage. It also cannot tell us how much amyloid would need to be removed for a lasting benefit. Those are important limits, not small details. Maya So it is a close comparison, but still a single case. Nora, how should listeners think about the value of a study this small? Nora A single case can help researchers see a possible pattern clearly. It can also suggest a question to test in a much larger group. Here, the contrast within the brain is striking because the regions were close to each other, but the biology of Alzheimer’s differs from person to person. One person cannot represent all those differences. The finding needs to be checked in more brains before researchers can know how often this pattern appears. The treatment history also matters. This man took part in a trial and received many doses over several years. His experience cannot tell us what would happen to every person who receives an amyloid-targeting drug. Nora Nor can the brain examination settle whether treatment helps patients in ways they notice in their lives. The finding is about the pattern of disease in this one brain. Alex That distinction helps with the wider treatment context. ScienceDaily reports that aducanumab received accelerated approval from the US Food and Drug Administration, or FDA, but is no longer sold. The same account says two later amyloid-targeting drugs, donanemab and lecanemab, received full FDA approval. Those drugs are related in their focus on amyloid, but this one brain study does not compare them or show how well they work. It should not be treated as a guide to an individual’s care. Maya The report also raises a question about how long researchers look for a treatment effect. Alex, what is the point there? Alex ScienceDaily says clinical trials commonly assess patients over about 18 months. The researchers raise the possibility that some protective effects could take longer to appear. This case offers a reason to ask whether longer follow-up might matter, because the man’s brain showed a regional contrast years after his last dose. But it does not establish that a longer trial would find a benefit, or that any benefit would be large enough to matter to patients. Nora And that is where the limits and the promise sit side by side. The examination gives researchers a detailed picture of what was present in different areas of one brain. It may help guide further research into how amyloid and tau relate to each other. But it cannot tell us whether the pattern would be the same in other people, what amount of amyloid removal matters, or whether the drug directly caused the difference. Maya Nora, your key point is that the brain offered a rare comparison: neighboring regions with different amyloid levels also showed different levels of tau and tissue damage. Alex, you’ve set that finding beside the limits of a single case and the question of longer follow-up. The result is a valuable clue, not a verdict on Alzheimer’s drugs. Thanks to both of you, and thanks for listening to Slow English FM.
